TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Subjects must meet ACR criteria for diagnosis of RA for at least 3 months, must meet ACR Functional Class I, II or III (1992 criteria) and must have a confirmed diagnosis of active moderate to severe rheumatoid arthritis as defined by 6 or more swollen joints and 9 or more tender joints;~* must also have DAS of 3.2 or greater at study entry,~* normal laboratory parameters and ESR \>20,~* satisfactory response or intolerance to one or more prior DMARDs and~* be willing and able to give informed consent.~Exclusion:~* Previous treatment with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibodies resulting in persistent CD4 lymphopenia,~* history of acute inflammatory joint disease other than RA,~* prior treatment with cyclophosphamide or chlorambucil,~* prior treatment with intravenous immunoglobulin within 70 days,~* history of malignant lymphoma,~* history of uncontrolled diabetes,~* unstable ischemic heart disease,~* active inflammatory bowel disease,~* active peptic ulcer disease or stroke,~* positive HIV status,~* positive serology for Hepatitis B or C,~* no previous history of tuberculosis or listeria infection,~* no previous history of cancer other than successfully treated skin cancer;~* women can not be pregnant or be breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of Type 1 or Type 2 diabetes and~* have 2 or more other chronic comorbidities~Exclusion Criteria:~* do not speak English~* have documented cognitive deficits~* unable to give informed consent~* have limited life expectancy (\<1 year)~* not available for follow-up~* seen primarily by a resident physician~* are pregnant or considering conception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shared decision-making aid (Type: EXPERIMENTAL): At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)
- Generic hard-copy diabetes resources (Type: PLACEBO_COMPARATOR): At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men over 20years of age~* More than 45kg body weight and ideal body weight within ±20% of the weight~* Screening was conducted within 14 days of investigational drug administration (Vital Sign \& Physical Examination, hematology and blood coagulation tests, blood chemistry tests, urinalysis, 12-lead ECG, etc.), the results at the discretion of the investigator deemed suitable for participation in clinical trials~* Written consent person who determines to participate in a clinical trial~Exclusion Criteria:~* A person who showed hypersensitivity when other preventive vaccination in the past~* A person who have received cholera vaccine in the past~* A person who had a febrile illness or infection disease, or have received antibiotics within 2weeks before the start of the experiment~* A person who had gastrointestinal symptoms such as diarrhea, abdominal pain, or have been received prescription drug within one week before the start of the experiment~* A person who was lasted for more than two weeks of symptoms such as diarrhea, abdominal pain within 6months before the start of the experiment~* A person who donate whole blood or component of blood within one months before the start of the experiment if the donors~* A person who received other preventive vaccine within 2months before the start of the experiment~* A person who received blood products of immune globulin preparations within 3months before the start of the experiment~* A person who has immune function disorders or are receiving immunosuppressive treatment~* A person who has chronic illness in progress~* Ongoing drug and alcohol abuse(Not more than 28 units/week for drinking)~* A person who participate in clinical trials treated with the investigational drug within 2months before the start of the experiment~* A person who is difficult to participate in this clinical trials as the discretion of the investigator

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Euvichol (Type: EXPERIMENTAL): Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Real-world Study of Imraldi® Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Initiation on Imraldi® therapy after 18th October 2018, as part of routine treatment immediately after transitioning from at least 16 weeks' treatment with originator adalimumab (Humira®)~* Availability of at least one Baseline disease score (i.e. within 16 weeks prior or up to 6 weeks post-initiation of Imraldi®)~* Should provide informed consent to participate in the study~Exclusion Criteria:~- Unlikely to attend for regular clinic visits for the duration of study follow-up, in the opinion of the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab Therapy (Type: None): Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III or IV cutaneous malignant melanoma~* HLA-A1 and/or HLA-A2 expression by serologic HLA typing~  * HLA-A2.1 subtype must be confirmed by polymerase chain reaction on genomic DNA obtained from peripheral blood mononuclear cells~* No active CNS metastases by CT scan or MRI~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* Karnofsky 60-100%~Life expectancy~* At least 4 months~Hematopoietic~* WBC greater than 2,500/mm\^3~* Neutrophil count greater than 1,000/mm\^3~* Lymphocyte count greater than 700/mm\^3~* Platelet count greater than 75,000/mm\^3~* Hemoglobin greater than 9 g/dL~* No bleeding disorders~Hepatic~* Bilirubin less than 2.0 mg/dL~* Hepatitis B surface antigen negative~* Hepatitis C antibody negative~Renal~* Creatinine less than 2.5 mg/dL~Cardiovascular~* No clinically significant heart disease~Pulmonary~* No clinically significant respiratory disease~Immunologic~* No active systemic infection~* No immunodeficiency disease~  * No evidence of HIV-1, HIV-2, or human T-cell lymphotropic virus-1~* No active autoimmune disease including (but not limited to):~  * Lupus erythematosus~ * Autoimmune thyroiditis or uveitis~ * Multiple sclerosis~ * Inflammatory bowel disease~Other~* Stable medical condition~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 1 month after study participation~* No organic brain syndrome or psychiatric illness that would preclude study compliance~* No other concurrent active malignancy~* No other concurrent serious illness that would preclude study treatment~* No contraindication to leukapheresis~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 4 weeks since prior immunotherapy~* No other concurrent immunotherapy~Chemotherapy~* More than 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas)~* No concurrent chemotherapy~Endocrine therapy~* No concurrent corticosteroids~Radiotherapy~* More than 4 weeks since prior radiotherapy~* No prior radiotherapy to the spleen~* Concurrent palliative radiotherapy allowed~Surgery~* Recovered from prior surgery~* No prior splenectomy~* No prior organ allograft~* Concurrent surgery on selected metastases (e.g., because of pain or local complications such as compression) allowed~Other~* No other concurrent investigational drugs~* No concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnosis of functional HoFH~2. If undergoing LDL apheresis, must have initiated LDL apheresis at least 3 months prior to screening and must have been on a stable weekly or every other week schedule and/or stable settings for at least 8 weeks~3. Willing to consistently maintain his/her usual low fat or heart-healthy diet for the duration of the study~Key Exclusion Criteria:~1. LDL-C level \<70 mg/dL (1.81 mmol/L) at the screening visit~2. Background medical Lipid Modifying Therapy (LMT) (if applicable) that has not been stable before the screening visit~3. Lipid-apheresis schedule /apheresis settings (if applicable) that have not been stable for at least 8 weeks before the screening visit~4. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a dose/amount that has not been stable for at least 4 weeks prior to the screening visit~5. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins~6. Newly diagnosed (within 3 months prior to randomization visit) diabetes mellitus or poorly controlled (HbA1c \>9%) diabetes~7. History of a MI, unstable angina leading to hospitalization, coronary artery bypass graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, valve replacement surgery, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior to the screening visit~8. Pregnant or breastfeeding women~9. Sexually active women of child bearing potential (WOCBP), who are unwilling to practice a highly effective birth control method prior to the initial dose, during the study, and for 24 weeks after the last dose of study drug~10. Men who are sexually active with women of child bearing potential (WOCBP) and are unwilling to consistently use condoms during the study drug treatment period and for 24 weeks after the last dose of study drug regardless of vasectomy status~Note: Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- evinacumab (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No evidence of HCV infection by HCV PCR (done at the time of the initial consent)~* Age\>60 yrs with an expected waiting time\>2 years; or~* Age\<60 yrs with any one of the following risk factors: Diabetes, coronary artery disease, peripheral artery disease and/or cerebrovascular disease~* Willingness to provide informed consent~* Absence of a living donor.~Exclusion Criteria:~* Estimated life expectancy of less than one year based on clinical judgment of the investigator~* Prior liver or renal transplantation~* Pregnant women~* Incarcerated patients~* Medical or social condition which in the opinion of the investigator will interfere with or prevent follow-up per protocol~* Unable or unwilling to return for follow-up visits~Donor Exclusion Criteria:~* HBV sAg positive~* HIV PCR or antibody positive~* HCV RNA negative

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HCV+ Donor Kidney Recipient (Type: EXPERIMENTAL): All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Isolation Device to Contain Aerosol During Aerosol Generating Procedures in the Operating Room

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective scheduled surgery (not emergent)~* Planned general anesthesia requiring intubation~Exclusion Criteria:~* Patients refusing or unable to consent for any reason, including claustrophobia or inability to cooperate~* Patients predicted to require the use of fiberoptic bronchoscopy for intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention group (Type: EXPERIMENTAL): This group will undergo airway management in the operating room as part of the anesthesia for surgery in the presence of the novel isolation device.
- Control group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Prophylaxis Before Surgery Versus After Cord Clamping in Elective Cesarean Delivery - a Double-blind, Prospective, Randomized Placebo-controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Elective cesarean section at term Patientin \>18 years Informed consent NO known allergy to cefazolin NO exposure to any antibiotic agent within 1 week prior to delivery~Exclusion Criteria:~- cesarean section before week 37 cephalosporin allergy age less than 18 years exposure to any antibiotic agent within 1 week prior to delivery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cefazolin A (Type: ACTIVE_COMPARATOR): administered before skin incision
- Cefazolin B (Type: ACTIVE_COMPARATOR): after umbilical cord clamping
- saline solution (Type: PLACEBO_COMPARATOR): administered before skin incision

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes, treated with diet and exercise, with or without metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to study screening.~* Have HbA1c \>6.5% to ≤11% at screening visit. If newly diagnosed and not on medicine for diabetes, HbA1c must be between \>6.5 % to ≤9%.~* Have a BMI (body mass index) \>85 percentile for age, gender and body weight ≥50 kilograms (110 pounds).~Exclusion Criteria:~* Known type 1 diabetes, or positive GAD65 or IA2 antibodies, or history of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome.~* A history of, or at risk for pancreatitis.~* Self or family history of Multiple Endocrine Neoplasia (MEN) type 2A or B, thyroid C-cell hyperplasia or medullary thyroid cancer, or a blood calcitonin result ≥20 picograms per milliliter (pg/ml) at screening.~* A systolic blood pressure of ≥160 millimeters of mercury (mmHg) or diastolic ≥100 mmHg.~* Active or treated cancer.~* A blood disorder where an accurate HbA1c may not be obtainable.~* A female of childbearing age, sexually active and not on birth control.~* Pregnant or plan to be pregnant during the study, or breastfeeding.~* Taking any diabetic medication other than metformin or basal insulin and have not stopped it 3 months prior to the screening visit (6 weeks for bolus or mealtime insulin).~* Have taken oral steroids within the last 60 days or more than 20 days use within the past year or 1000 micrograms fluticasone propionate per day.~* Using prescription weight loss medications in the last 30 days, or plan to use.~* Taking psychiatric medications for depression or illness or attention deficit hyperactivity disorder (ADHD) if, the doses has changed within the last 3 months.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/0.75 milligram (mg) Dulaglutide (Type: EXPERIMENTAL): Participants received placebo administered subcutaneously (SC) for 26 weeks during the double-blind period and open-label 0.75 mg/week dulaglutide for 26 weeks during the Open Label Extension (OLE).
- 0.75 mg Dulaglutide (Type: EXPERIMENTAL): Participants received 0.75 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 0.75 mg/week for 26 weeks during the OLE.
- 1.5 mg Dulaglutide (Type: EXPERIMENTAL): Participants received 1.5 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 1.5 mg/week for 26 weeks during the OLE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete